<DOC>
	<DOCNO>NCT03096340</DOCNO>
	<brief_summary>IT141 novel nanoparticle formulation SN-38 , active metabolite irinotecan , intend deliver drug tumor reduce toxicity normal tissue . The study design determine maximum tolerate dose ( MTD ) IT-141 , investigate pharmacokinetic ( PK ) parameter possible pharmacodynamics ( PD ) relationship . Patients also monitor response therapy .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study IT-141 Monotherapy Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>10-hydroxycamptothecin</mesh_term>
	<criteria>Must 18 year age old . Must male nonpregnant female agree comply applicable contraceptive requirement protocol . Must histologically cytologically confirm , incurable malignancy , standard treatment currently available . Must measurable evaluable disease dose escalation phase ( measurable disease prefer expanded cohort MTD reach ) . Must anticipate survival least 12 week . Must fully inform regard illness investigational nature study protocol , must sign Institutional Review Board ( IRB ) approve Informed Consent Form ( ICF ) . Must ambulatory , Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . Must adequate organ function , define follow : Hematologic : ANC 1.5 x 109/L , Hgb ≥ 9.0 g/dL platelet count 100 x 109/L ( platelet count &gt; 75 x 109/L documented evidence bone marrow involvement ) . Hepatic : Total bilirubin 1.5 x ULN ; transaminases ≤ 2.5 x ULN ( may 5 x ULN clearly due liver metastasis ) ; prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 2 x ( ULN ) . Renal : Serum creatinine 1.5 x ULN creatinine clearance 60 mL/min . Must stable dos drug affect hepatic drug metabolism renal drug excretion ( e.g . nonsteroidal antiinflammatory drug , corticosteroid , barbiturate , diphenylhydantoin , narcotic analgesic , probenecid ) . Such drug initiate less 30 day prior Baseline/C1D1 time study participation . Whenever possible , narcotic analgesic dos stable within 30 day prior study entry first cycle therapy . Must recover reversible side effect prior therapy ( e.g . major surgery , antineoplastic experimental therapy , significant radiation therapy hematopoietic site within 4 week Baseline/C1D1 , nitrosoureas nitrogen mustard within 6 week Baseline/C1D1 ) Must understand able , willing , likely fully comply study procedure restriction . Current recurrent disease could affect action disposition IT141 , clinical laboratory assessment . Subjects UGT1A1*28 polymorphism . Current relevant previous history serious , severe unstable ( acute progressive ) physical psychiatric illness , include medical disorder may require treatment make subject unlikely fully complete study , condition present undue risk IP procedure . Primary brain tumor know brain metastasis unless clinically stable stable reduce dos steroid . Frequent vomiting . Recent history unintentional weight loss &gt; 10 % current body weight past 3 month . Ongoing radiation therapy , chemotherapy , hormonal therapy . Point radiation site bone pain allow . Current ( within 1 week Screening ) regular use medication ( include overthecounter ( OTC ) , herbal homeopathic preparation ) could improve worsen cancer study , could affect action disposition IT141 , clinical laboratory assessment ; e.g . Coumadin therapy , due high competitive protein binding . Subjects take ANY supplemental IRON , i.e. , therapeutic part multivitamin regimen , exclude study , whether prescribe selfmedicated . Concomitant use UGT1A1 inhibitor , idinavir , atazanavir sorafenib , throughout study period . Known suspect intolerance hypersensitivity IT141 state ingredient . History alcohol substance abuse within last year . History use another IP within last 4 week prior enrollment . Female subject pregnant lactating , include female positive pregnancy test screening . Previous enrollment study , follow withdrawal reason . Known HIVpositive subject combination antiretroviral therapy due potential PK interaction study agent . Evidence ischemia myocardial infarction within past 6 month , significant abnormality ECG . A QTc interval outside normal . ( Normal : &lt; 450 msec male &lt; 460 msec female )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SN-38</keyword>
	<keyword>irinotecan</keyword>
</DOC>